オビヌツズマブ
↑ “Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity”. Nature Biotechnology 17 (2): 176–80. (February 1999). doi:10.1038/6179. PMID 10052355.
↑ WHO Drug Information, Vol. 22, No. 2, 2008 Proposed INN: List 99, page 123
↑ “Roche - Roche acquires Swiss based GlycArt Biotechnology to strengthen expertise in therapeutic antibody research”. roche.com. 2015年2月5日時点のオリジナルよりアーカイブ。2015年4月29日閲覧。
↑ Presentation: GlycArt Biotechnology AG From Inception to trade sale – and what happened after... by Dr. Joël Jean-Mairet. Brussels, March 31, 2011
1 2 3 “Obinutuzumab: first global approval”. Drugs 74 (1): 147–54. (January 2014). doi:10.1007/s40265-013-0167-3. PMID 24338113.